Journal of Cancer Research and Clinical Oncology

, Volume 122, Issue 4, pp 219–222

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2

  • Mami Takahashi
  • Masato Fukutake
  • Shigeru Yokota
  • Kaori Ishida
  • Keiji Wakabayashi
  • Takashi Sugimura
Original Paper Experimental Oncology

Abstract

Non-steroidal anti-inflammatory drugs, such as piroxicam and sulindac, are known to inhibit development of aberrant crypt foci (ACF) and cancer in the colon. However, these agents cause gastrointestinal side-effects. Nimesulide is a selective inhibitor of cyclooxygenase 2 and has been shown to have a more potent anti-inflammatory action than piroxicam, but be less ulcerogenic and, therefore, a potentially more useful chemopreventive agent. To assess this possibility the inhibitory effects of nimesulide on the formation of ACF induced by azoxymethane in rat colon were investigated, and compared with those of piroxicam and sulindac. Male F344 rats were treated s.c. with 15 mg/kg body weight azoxymethane once a week for 2 weeks and given 50, 100 or 200 ppm nimesulide, 200 ppm piroxicam, or 200 ppm sulindac in their diet from the day before the first carcinogen treatment until the end of the experiment at week 4. At this time, nimesulide at doses of 50, 100 and 200 ppm had reduced the numbers of azoxymethane-induced ACF to 75%, 71% and 65% respectively compared to the control. The number of azoxymethane-induced ACF per colon in the group given 200 ppm nimesulide was almost the same as in those given 200 ppm piroxicam, and lower than that in the group given 200 ppm sulindac. These results suggest that nimesulide, a selective cyclooxygenase 2 inhibitor, warrants attention as a candidate for chemopreventive agent with low toxicity, active against colon carcinogenesis.

Key words

Nimesulide Cyclooxygenase 2 Aberrant crypt foci Azoxymethane Rat colon carcinogenesis 

Abbreviations

ACF

aberrant crypt foci

COX

cyclooxygenase

NSAID

non-steroidal anti-inflammatory drugs

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bird RP (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147–151Google Scholar
  2. Böttcher I, Schweizer A, Glatt M, Werner H (1987) A sulphonamido-indanone derivative CPG 28237 (ZK 34228), a novel nonsteroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats. Drugs Exp Clin Res 13: 237–245Google Scholar
  3. Broder S (1993) Perspectives on cancer in Japan and the United States. Jpn J Cancer Res 84: 821–830Google Scholar
  4. Cipollini F, Mecozzi V, Altilia F (1989) Endoscopic assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr Ther Res 45: 1042–1048Google Scholar
  5. Copeland RA, Williams JM, Giannaras J, Nurnberg S Covington M, Pinto D, Pick S, Trzaskos JM (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 91: 11202–11206Google Scholar
  6. DuBois RN, Awad J, Morrow J, Roberts LJ, II, Bishop R (1994) Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. Clin Invest 93: 493–498Google Scholar
  7. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188Google Scholar
  8. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 55: 2556–2559Google Scholar
  9. Labyle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639Google Scholar
  10. Langman MJS (1989) Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 96: 640–646Google Scholar
  11. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91: 3228–3232Google Scholar
  12. Meade EA, Smith WL, DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610–6614Google Scholar
  13. Mereto E, Frencia L, Ghia M (1994) Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Lett 76: 5–9Google Scholar
  14. Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE (1994) Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049–1054Google Scholar
  15. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA (1991) Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 51: 1564–1567Google Scholar
  16. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55: 1464–1472Google Scholar
  17. Reddy BS, Maruyama H, Kelloff G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drugs, during different stages of rat colon tumor development. Cancer Res 47: 5340–5346Google Scholar
  18. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G (1992) Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019–1023Google Scholar
  19. Reddy BS, Rao CV, Rivenson A, Kelloff G (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493–1497Google Scholar
  20. Reitz DB, Li JJ, Norton MB, Reinhard EJ, Collins JT, Anderson GD, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Isakson PC (1994) Selective cyclooxygenase inhibitors: novel 1,2-diaryl-cyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 37: 3878–3881Google Scholar
  21. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518–523Google Scholar
  22. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR (1991) Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 22: 287–294Google Scholar
  23. Swingle KF, Moore GGI (1984) Preclinical pharmacological studies with nimesulide. Drugs Exp Clin Res 10: 587–597Google Scholar
  24. Takahashi M, Minamoto T, Yamashita N, Yazawa K, Sugimura T, Esumi H (1993) Reduction in formation and growth of 1,2-dimethylhydrazine-induced aberrant crypt foci in rat colon by docosahexaenoic acid. Cancer Res 53: 2786–2789Google Scholar
  25. Takahashi S, Ogawa K, Ohshima H, Esumi H, Ito N, Sugimura T (1991) Induction of aberrant crypt foci in the large intestine of F344 rats by oral administration of 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine. Jpn J Cancer Res 82: 135–137Google Scholar
  26. Taniguchi Y, Ikesue A, Yokoyama K, Noda K, Debuchi H, Nakamura T, Toda A, Shimeno H (1995) Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in-vitro. Pharm Sci 1: 173–175Google Scholar
  27. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593–1596Google Scholar
  28. Tofanetti O, Casciarri I, Cipolla PV, Cazzulani P, Omini C (1989) Effect of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 17: 745–746Google Scholar
  29. Tudek B, Bird RP, Bruce WR (1989) Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 49: 1236–1240Google Scholar
  30. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692–2696Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Mami Takahashi
    • 1
  • Masato Fukutake
    • 1
  • Shigeru Yokota
    • 1
  • Kaori Ishida
    • 1
  • Keiji Wakabayashi
    • 1
  • Takashi Sugimura
    • 1
  1. 1.Biochemistry DivisionNational Cancer Center Research InstituteTokyoJapan

Personalised recommendations